Overview

Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
Phase:
Phase 2
Details
Lead Sponsor:
Sunovion
Treatments:
Eszopiclone